Skip to main content
Premium Trial:

Request an Annual Quote

Personalis, UCSF to Study ctDNA Utility in Colorectal Cancer Treatment Response Monitoring

NEW YORK – Personalis said Wednesday that it has partnered with the University of California, San Francisco to study its liquid biopsy assay, NeXT Personal, in patients with colorectal cancer.

Investigators will employ the firm's personalized residual disease and monitoring assay — currently for research use only — to discover circulating tumor DNA signals associated with treatment response and adverse events in a cohort of late-stage CRC patients receiving capecitabine in combination with Merck's Keytruda (pembrolizumab) and Genentech's Avastin (bevacizumab).

Financial terms of the collaboration were not disclosed.

"Assessment of early response and adaptive resistance both critically require a noninvasive liquid biopsy-based assay that can confidently detect changes in the abundance and mutational profile of cancer cells," Lawrence Fong, leader of UCSF's cancer immunotherapy program, said in a statement.

According to Richard Chen, Personalis' chief medical officer, the company also hopes to use the study to determine optimal sample collection timing for early identification of complete response and demonstrate that this has clinical utility. The firm hopes to lay the groundwork for future interventional studies that can use early detection of response to guide "rapid changes to treatment," he said in a statement.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.